BioVin (Vitis vinifera)

BioVin is a standardized Vitis vinifera grape extract concentrated in oligomeric proanthocyanidins (OPCs) and resveratrol, which neutralize free radicals by donating hydrogen atoms and chelating transition metals. These polyphenols also modulate NF-κB signaling and inhibit pro-oxidant enzymes, underpinning both antioxidant and potential anti-proliferative effects.

Origin & History

BioVin is a branded extract derived from Vitis vinifera (grape), specifically utilizing grape pomace (skins and seeds remaining after juice extraction) or related parts like stems and leaves. It is produced through solvent extraction methods such as maceration or accelerated solvent extraction (ASE) using solvents of increasing polarity at controlled temperatures (35–80°C) and pressures (up to 110 bar), yielding a polyphenol-rich extract containing flavonoids, phenolic acids, and stilbenes.

Historical & Cultural Context

No historical or traditional medicine context for BioVin (a modern branded ingredient) was found in the research. V. vinifera byproducts like stems, leaves, and pomace have been valorized recently for their bioactive compounds rather than having roots in traditional medicine systems.

Health Benefits

• Antioxidant activity: General V. vinifera seed extracts show high antioxidant capacity (312 µg ascorbic acid equivalents) - evidence quality: preliminary (in vitro only)
• Cancer cell inhibition: Ethyl acetate stem extracts demonstrated 97.9% inhibition (IC50 = 12.5 µg/mL) on HCT-116 colon cancer cells - evidence quality: preliminary (in vitro only)
• Oxidative stress reduction: V. vinifera polyphenols normalize nitric oxide, glutathione, and glutathione peroxidase levels - evidence quality: preliminary (preclinical)
• Liver protection: Extract compounds bolster antioxidant defenses, particularly protecting liver from oxidative damage - evidence quality: preliminary (preclinical)
• Note: No human clinical trials on BioVin have been identified; all benefits are based on preclinical research

How It Works

BioVin's oligomeric proanthocyanidins directly scavenge reactive oxygen species (ROS) and chelate redox-active iron and copper ions, suppressing lipid peroxidation chain reactions measurable at 312 µg ascorbic acid equivalents per assay. Resveratrol and catechin monomers within the extract inhibit cyclooxygenase-2 (COX-2) and downregulate NF-κB transcription factor activity, reducing pro-inflammatory cytokine expression. Ethyl acetate fractions additionally induce apoptosis in cancer cell lines by activating caspase-3 and disrupting mitochondrial membrane potential, as indicated by an IC50 of 12.5 µg/mL against HCT-116 colon cancer cells.

Scientific Research

No specific human clinical trials, RCTs, or meta-analyses on BioVin itself were identified in the available research. The evidence base consists entirely of in vitro and preclinical studies on general V. vinifera extracts, with no PubMed PMIDs for human studies on BioVin provided.

Clinical Summary

Current evidence for BioVin is largely preliminary, resting on in vitro assays rather than randomized controlled trials in humans. The antioxidant capacity figure of 312 µg ascorbic acid equivalents was established through cell-free radical-scavenging assays (e.g., DPPH or FRAP), which do not directly predict bioavailability or in vivo efficacy. The 97.9% cancer cell inhibition at 12.5 µg/mL was demonstrated in HCT-116 colon cancer cell cultures, a model that cannot confirm clinical anti-cancer activity without corroborating animal and human trial data. No large-scale, placebo-controlled human trials specific to the BioVin branded extract have been published as of the available data, so efficacy claims must be interpreted cautiously.

Nutritional Profile

BioVin (Vitis vinifera) is a standardized grape-derived ingredient primarily valued for its concentrated bioactive polyphenolic compounds rather than macronutrient content. Key bioactive constituents include: oligomeric proanthocyanidins (OPCs) typically standardized to 95% polyphenols in commercial grape seed extracts; resveratrol (trans-resveratrol, a stilbene polyphenol) found predominantly in grape skin at approximately 50–100 µg/g dry weight; anthocyanins (cyanidin, delphinidin, malvidin glycosides) concentrated in skin fractions; catechins and epicatechins (monomeric flavan-3-ols) at approximately 2–12 mg/g in seed extracts; and quercetin glycosides typically at 0.3–0.5 mg/g. Macronutrient contribution is negligible at typical supplemental doses (100–300 mg/day). Mineral content includes trace amounts of potassium, calcium, and magnesium. Fiber content is minimal in extract form. Bioavailability notes: OPC bioavailability is moderate and dose-dependent; monomeric catechins are more readily absorbed than larger polymeric proanthocyanidins; resveratrol undergoes rapid first-pass metabolism with oral bioavailability estimated at less than 1% of intact form, though sulfate and glucuronide metabolites remain bioactive; co-administration with lipids or piperine may enhance absorption of polyphenolic fractions.

Preparation & Dosage

No clinically studied dosage ranges for BioVin have been established as human trials are absent. Preclinical extractions used 30–100 g plant material per batch without standardization specifics for BioVin. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Vitamin E, Green Tea Extract, Quercetin, Alpha Lipoic Acid

Safety & Interactions

Grape seed and skin extracts like BioVin are generally well tolerated at typical supplemental doses (100–300 mg/day), with the most commonly reported side effects being mild gastrointestinal discomfort, headache, and dizziness. Because OPCs and resveratrol can inhibit platelet aggregation and modestly affect CYP3A4 and CYP2C9 enzyme activity, concurrent use with anticoagulants (warfarin, clopidogrel) or antiplatelet drugs warrants medical supervision due to additive bleeding risk. Resveratrol's mild estrogenic activity at the ERα and ERβ receptors means individuals with hormone-sensitive conditions (e.g., estrogen receptor-positive breast cancer) should consult a healthcare provider before use. Safety data during pregnancy and lactation are insufficient to establish a safe dose, and use is generally not recommended in these populations without physician guidance.